Abstract Library

#1818 Patient Outcomes after Cardiac Surgery for Carcinoid Heart Disease Are Dependant Upon Successful Cytoreductive Multimodal Treatment and Control of Metastatic Neuroendocrine Disease

Introduction: Carcinoid Heart Disease (CHD) as a result of long standing carcinoid syndrome is associated with a poor prognosis due to development of valvular incompetence & right heart failure. Cardiac valve surgery is the main therapeutic option.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Jaber B, Ramsey E, Cowburn P, Tsang G, Armstrong T,

Keywords: Carcinoid heart disease, surgery,

#1273 Tissue Prognostic Markers in Pancreatic Neuroendocrine Tumours

Introduction: Pancreatic neuroendocrine tumours (pNETs) are a rare, heterogeneous class of neoplasms, with a rising incidence. Prognosis is variable with 5-year survival as low as 16% in inoperable tumours.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Dunbar J

Authors: Dunbar J, Tod J, Horne J, Armstrong T, Cave J,

Keywords: Pancreatic, microenvironment, prognosis,

#1148 Ki67 as a Prognostic Marker in Neuroendocrine Tumours: A Systematic Review of the Literature and Quantitative Synthesis of 5 year Survival Data

Introduction: The ENETS guidelines classify Gastroenteropancreatic Neuroendocrine Tumours (GEP NETs) according to the histological assessment of tumour mitotic count or Ki67 labelling index (LI) on paraffin-embedded tissue, because proliferation rate has been shown to strongly correlate with prognosis. Since the guidelines were published, Ki67 has been established as the more reproducible measure, and further large case series have been reported.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Cave J

Authors: Richards-Taylor S, Tilley C, Hu J, Pearce N, Armstrong T,

Keywords: GEP-NET, prognosis, Ki67,

#1144 Aggressive Multi-Modality Treatment of Pancreatic Neuroendocrine Tumors (pNETs): Outcomes in Patients with Advanced Disease

Introduction: pNETs carry the worst prognosis of all NETs, particularly when hepatic metastasis are present. We try to actively treat all patients referred.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Mayo D

Authors: Mayo D, Armstrong T, Cave J, Nolan L, Steadman B,

Keywords: pNET, multimodal, Neuroendocrine,

#497 Metastatic Pancreatic Neuroendocrine Carcinoma: Does Aggressive Surgical Intervention Improve Outcome?

Introduction: Pancreatic neuroendocrine tumors (PNETS) often present late. At diagnosis, 65% of patients have metastases, with median survival of 24 months. The conventional approach is conservative management. Recent evidence has suggested that aggressive treatment leads to better outcomes.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: White M, Edwards L, Cawich S, Abu-Hilal M, Armstrong T,

Keywords: pancreatic, surgery,